<DOC>
	<DOCNO>NCT02584140</DOCNO>
	<brief_summary>The purpose study test program use drug level monitoring , text messaging ( `` iTAB '' ) personalize counsel HIV prevention service , include PrEP ( medicine help prevent HIV infection take daily ) .</brief_summary>
	<brief_title>PrEP Adherence Enhancement Guided iTAB Drug Levels Women</brief_title>
	<detailed_description>This open-label single-arm longitudinal clinical trial estimate medication adherence retention PrEP HIV prevention program implement combination intervention strategy use text-messages ( iTAB ) stag adherence counsel support strategy titrate real-time drug level woman at-risk HIV acquisition . A total 135 participant receive combine intervention text message adherence reminder adherence support . The text messaging system consist daily , personalize , automate 2-way text message maintain adherence retention . Participants low intracellular tenofovir diphosphate ( TFV-DP ) concentration receive escalate , target adherence support . All participant receive access PrEP accordance standardize comprehensive method prescribe clinical assessment include safety monitoring well regular HIV sexually transmit infection ( STI ) screening . All participant follow 48 week enrollment receive post study follow-up 60 week . The primary endpoint measure 48 week .</detailed_description>
	<criteria>Female birth identifies female gender Age 18 year older Able understand provide consent English Spanish HIV negative 4th generation test ( Ag/Ab test ) combination EIA HIV RNA Creatinine clearance ≥ 60 ml/min ( via CockcroftGault formula ) AtRisk Criteria ( least one ) : Condomless sex last 3 month one male partner unknown HIV status know substantial risk HIV infection ( IDU , bisexual , sex good , recently incarcerate , country HIV prevalence &gt; 1 % , interpersonal Partner Violence ) ; STI ( rectal vaginal gonorrhea syphilis ) diagnosis last 6 month . Previous postexposure prophylaxis ( PEP ) use last 12 month . Has least one HIVinfected sexual partner ≥4 week . Sex exchange money , good service Pregnancy enrollment . Any condition , opinion provider , seriously compromise participant 's ability comply protocol , include adherence PrEP medication dosing , active , untreated unstable major mental illness ( i.e . untreated psychotic disorder ) . Use prohibit medication , particular , agent know nephrotoxic drug slow renal excretion . Previous participation HIV vaccine trial . Participants document received placebo exclude . Signs symptoms suspicious Primary HIV Infection ( PHI ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>PrEP</keyword>
	<keyword>Pre-exposure Prophylaxis</keyword>
	<keyword>HIV Prevention</keyword>
</DOC>